Vara, a company based in Berlin that focuses on AI-driven breast cancer detection, has successfully secured €8 million (around $8.9 million) in a Series B funding round. This funding was co-led by Smart Family Office, FJH, and IBB Ventures, and it aims to help Vara achieve its ambitious goal of revolutionizing breast cancer screening through the power of artificial intelligence.
The firm’s cutting-edge AI software has been shown to outperform the average radiologist in identifying breast cancer. Currently, this technology is part of Germany’s National Breast Cancer Screening Program, helping over 80,000 women each month. This impressive reach highlights its potential to enhance screening procedures and improve patient outcomes significantly.
Looking beyond its achievements in Germany, Vara is now eyeing growth in emerging markets, particularly in India. They have teamed up with NM Medical, a leading provider of imaging services, to bolster early breast cancer detection and improve preventive care standards for women in the region.
Jonas Muff, CEO of Vara, stated, “This raise, which is particularly significant in today’s economic climate, not only validates our technology but enables us to accelerate Vara’s expansion for global impact. We’re extremely pleased with the outcomes we’re already seeing with our partners in healthcare, and we look forward to sharing more progress soon.”
Several other notable companies are also making strides in breast cancer detection:
Gabbi is on a mission to eliminate late-stage breast cancer by helping every woman understand her risk and ensuring access to early detection. Through a quick two-minute assessment, Gabbi’s platform creates a tailored care plan, serving as a virtual breast specialist via telehealth.
Celbrea focuses on the early detection of breast disease globally, specifically breast cancer. This FDA-cleared Class I medical device provides a painless and easy-to-use solution that alerts both physicians and patients to potential breast issues within just 15 minutes.
Syantra is making waves with its innovative blood test, Syantra DX, which aims to improve early breast cancer detection. Designed to be rapid, affordable, and precise regardless of age, family history, or breast tissue density, this groundbreaking test offers hope to many women who might otherwise have limited options for early diagnosis.
Reimagine Care is reshaping cancer care delivery by prioritizing affordability, accessibility, and a patient-centered approach. Established in 2020, this innovative company collaborates with healthcare systems and independent oncology practices to promote value-based care in community settings. Reimagine Care aims to enhance the quality of cancer treatment through expert staff, streamlined processes, and an advanced technology platform.
These companies, including Vara, are collectively contributing to a future where breast cancer detection is not only more effective but also more widely accessible.